Avidity Biosciences Inc

Company Profile

Avidity Biosciences Inc had its IPO on 2013-06-28 under the ticker symbol RNA.

The company operates in the Healthcare sector and Biotechnology industry. Avidity Biosciences Inc has a staff strength of 186 employees.

Stock update

Shares of Avidity Biosciences Inc opened at $6.87 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $6.84 - $7.28, and closed at $7.21.

This is a +9.74% increase from the previous day's closing price.

A total volume of 1,188,352 shares were traded at the close of the day’s session.

In the last one week, shares of Avidity Biosciences Inc have slipped by -9.42%.

Avidity Biosciences Inc's Key Ratios

Avidity Biosciences Inc has a market cap of $486.81 million, indicating a price to book ratio of 1.5762 and a price to sales ratio of 118.9953.

In the last 12-months Avidity Biosciences Inc’s revenue was $9.80 million with a gross profit of $-141180000 and an EBITDA of $-206712992. The EBITDA ratio measures Avidity Biosciences Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Avidity Biosciences Inc’s operating margin was -2126.37% while its return on assets stood at -25.25% with a return of equity of -41.45%.

In Q2, Avidity Biosciences Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 6.3%.

Avidity Biosciences Inc’s PE and PEG Ratio

Forward PE

0

Trailing PE

0

PEG

0

Its diluted EPS in the last 12-months stands at $-3.05 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Avidity Biosciences Inc’s profitability.

Avidity Biosciences Inc stock is trading at a EV to sales ratio of 24.0656 and a EV to EBITDA ratio of -1.2266. Its price to sales ratio in the trailing 12-months stood at 118.9953.

Avidity Biosciences Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets

$610.78 million

Total Liabilities

$45.24 million

Operating Cash Flow

$0

Capital Expenditure

$622000

Dividend Payout Ratio

0%

Avidity Biosciences Inc ended 2024 with $610.78 million in total assets and $0 in total liabilities. Its intangible assets were valued at $610.78 million while shareholder equity stood at $559.18 million.

Avidity Biosciences Inc ended 2024 with $0 in deferred long-term liabilities, $45.24 million in other current liabilities, 7000.00 in common stock, $-457963000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $153.88 million and cash and short-term investments were $576.50 million. The company’s total short-term debt was $3,151,000 while long-term debt stood at $0.

Avidity Biosciences Inc’s total current assets stands at $594.53 million while long-term investments were $0 and short-term investments were $422.62 million. Its net receivables were $0 compared to accounts payable of $5.65 million and inventory worth $0.

In 2024, Avidity Biosciences Inc's operating cash flow was $0 while its capital expenditure stood at $622000.

Comparatively, Avidity Biosciences Inc paid $0 in dividends in 2024.

Other key metrics

Current Trading Price

$7.21

52-Week High

$25.74

52-Week Low

$6.4

Analyst Target Price

$36

Avidity Biosciences Inc stock is currently trading at $7.21 per share. It touched a 52-week high of $25.74 and a 52-week low of $25.74. Analysts tracking the stock have a 12-month average target price of $36.

Its 50-day moving average was $9.09 and 200-day moving average was $14.97 The short ratio stood at 24.51 indicating a short percent outstanding of 0%.

Around 455.9% of the company’s stock are held by insiders while 10839% are held by institutions.